Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.

Molecular biology reports - 1 May 2013

Li Qiaoxin, Zhu Yao, He Jing, Wang Mengyun, Zhu Meiling, Shi Tingyan, Qiu Lixin, Ye Dingwei, Wei Qingyi

Abstract excerpt

Steroid 5-α-reductase type 2 (SRD5A2) V89L and A49T polymorphisms are thought to play a crucial role in the androgen synthesis and metabolic pathway, but their associations with prostate cancer risk remain controversial. To provide a more precise estimation of the associations between V89L and A49T polymorphisms and prostate cancer risk, we performed a meta-analysis using all published case-control studies of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Odds Ratio

Share to Polymorphism, Single Nucleotide

Share to Prostatic Neoplasms

Share to Publication Bias

Source

Identifiers

PMID: 23277398
DOI: 10.1007/s11033-012-2434-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.PMID 23277398Read ↗

Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.Semantic proximity Read ↗

Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.Semantic proximity Read ↗

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.Semantic proximity Read ↗

5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.Semantic proximity Read ↗

No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.Semantic proximity Read ↗

A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.Semantic proximity Read ↗

Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.Semantic proximity Read ↗

Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.